High-Speed AFM Reveals IDR-Mediated Structural Plasticity of EML4-ALK Modulated by ALK Inhibitors
Authors:
- Xujun HanXHXujun Han
- Noriyuki KoderaNKNoriyuki Kodera
- Neval YilmazNYNeval Yilmaz
- Katsuya SakaiKSKatsuya Sakai
- Sachiko AraiSASachiko Arai
- Borui LiBLBorui Li
- Ryu ImamuraRIRyu Imamura
- Dominic Chih-Cheng VoonDVDominic Chih-Cheng Voon
- Koji FukudaKFKoji Fukuda
- Shigeki NanjoSNShigeki Nanjo
- Holger FlechsigHFHolger Flechsig
- Hiroyuki ManoHMHiroyuki Mano
Preprint
Abstract
EML4-ALK is a key oncogenic driver in lung cancer, but variant-specific chemoresistance limits the efficacy of current ALK inhibitors. Because the N-terminus contains an intrinsically disordered region (IDR), how ALK inhibitors affect the structure and dynamics of full-length EML4-ALK remains unclear. Here, using high-speed atomic force microscopy (HS-AFM), we visualize the overall structures of three full-length EML4-ALK variants (v1, v3, and v5) at the single-molecule level. We identified a transient globular subdomain (residues 191–217) within the v3 IDR that contributes to distinct oligomerization patterns. Notably, ALK inhibitors compact the IDR subdomain and reduce oligomerization, whereas this effect is abolished by the resistance mutation ALK G1202R , suggesting that ALK inhibitors not only affect kinase activity but also modulate IDR dynamics. Our findings shed new light on the structural regulation of EML4-ALK and provide a foundation for developing next-generation targeted therapies that account for IDR-driven molecular behavior. Teaser: High-speed AFM revealed the full-length EML4-ALK structures and their IDR-mediated plasticity caused by ALK kinase inhibitorsKeywords
This publication has 36 references indexed in Scilit:
- Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)Journal of Thoracic Oncology, 2022
- Kinase-mediated RAS signaling via membraneless cytoplasmic protein granulesCell, 2021
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialThe Lancet, 2017
- Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCClinical Lung Cancer, 2016
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialThe Lancet Oncology, 2016
- Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsCellular and Molecular Life Sciences, 2016
- Intrinsically disordered proteins are potential drug targetsCurrent Opinion in Chemical Biology, 2010
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal of Cancer, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Sequence complexity of disordered proteinProteins: Structure, Function, and Bioinformatics, 2000